< Back to all clusters
[HEALTH] · United States · 52 sources

started · updated

Moderna's mFlusiva mRNA Flu Vaccine Approved by US FDA

The U.S. Food and Drug Administration has granted approval to Moderna’s mFlusiva, the first seasonal influenza vaccine that uses messenger‑RNA technology. The approval covers adults aged 50‑64 with full approval based on a late‑stage trial of about 40,000 participants that showed roughly a 27 % reduction in flu cases compared with a standard vaccine. Adults 65 and older receive accelerated approval, relying on a smaller study that demonstrated a strong immune response versus a high‑dose flu shot, with a confirmatory trial required. No major safety concerns were identified; the most common adverse events were mild injection‑site pain, fever, headache, fatigue and muscle aches. An independent FDA advisory committee voted unanimously in June to recommend the vaccine. After an earlier refusal to file, the agency reversed its decision following industry pressure and a public dispute. Moderna expects limited supplies of mFlusiva to reach selected retailers for the 2026‑27 flu season. Health Secretary Robert F. Kennedy Jr. has publicly criticized mRNA vaccines, but the FDA’s approval marks a significant milestone for seasonal flu prevention in the United States.

Entities

Adults aged 50 and older · Food and Drug Administration · Food and Drug Administration (FDA) · Moderna · Moderna Inc. · Robert F. Kennedy Jr. · Stéphane Bancel · U.S. Food and Drug Administration · U.S. Food and Drug Administration (FDA) · United States · mFLUSIVA · mFlusiva (mRNA‑1010)

Claims

What the coverage asserts, and how many sources carry each claim.

Sources